Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DermTech, Inc. - Common Stock (NQ:DMTK)

0.0940 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about DermTech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of DermTech, Inc. (DMTK) Investors
From Kirby McInerney LLP
Via Business Wire
DMTK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
DERMTECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DermTech, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
DermTech, Inc. (NASDAQ:DMTK) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 08/29/2023 -- Certain directors of DermTech, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of DermTech, Inc. (DMTK) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of DermTech, Inc. (DMTK) Investors
From Law Offices of Howard G. Smith
Via Business Wire
DMTK CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against DermTech, Inc.
From The Law Offices of Frank R. Cruz
Via Business Wire
DMTK CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
DermTech Announces Release Date for Third-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DermTech, Inc. (DMTK) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of DermTech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of DermTech, Inc. (DMTK) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of DermTech, Inc. (DMTK) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
DermTech Appoints Mark Aguillard as Chief Commercial Officer
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Reports Second-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Second-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations
From DermTech, Inc.
Via Business Wire
ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.